# Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

> **NCT02223117** · EARLY_PHASE1 · COMPLETED · sponsor: **Cellphire Therapeutics, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Thrombosomes
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02223117
- **Lead sponsor:** Cellphire Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-07-21
- **Final completion:** 2016-07-21
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02223117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02223117, "Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02223117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*